Q-omics provides the consensus-scored PSAPL1 profile across patient tissues and cancer cell-line models. PSAPL1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSAPL1 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, PSAPL1 RNA expression shows 9,506 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where PSAPL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSAPL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSAPL1 survival associations across molecular data types. PSAPL1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSAPL1 RNA expression–survival associations across cancer types. High PSAPL1 expression shows unfavorable associations in KIRC, SKCM, STAD, KICH and LIHC, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSAPL1 RNA expression.
This table summarizes PSAPL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PSAPL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSAPL1 shows lower tumor expression in LUAD, LUSC and STAD and higher tumor expression in BRCA, PAAD and COAD. The LUAD box plot shows higher PSAPL1 RNA expression in normal versus tumor tissue (log2 FC = −0.844, t-test p < 0.001).
This table shows molecular features associated with PSAPL1 in patient tissues and cancer cell lines. In patient samples, PSAPL1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PSAPL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
